Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 50Stomach Neoplasms 7Neoplasm Metastasis 5Colorectal Neoplasms 4Uterine Cervical Neoplasms 3HER2-positive Breast Cancer 3Esophageal Neoplasms 3Uterine Neoplasms 2Solid Tumors 2Lung Neoplasms 2Inflammatory Breast Neoplasms 2Gallbladder Neoplasms 2Endometrial Neoplasms 2Cholangiocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Brain Neoplasms 2Biliary Tract Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Adenocarcinoma Of Esophagus 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Cancer 1Rectal Neoplasms 1Prostatic Neoplasms 1Patient Compliance 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Advanced Breast Carcinoma × Trastuzumab × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡